Once heralded as the Holy Grail, the capability of obtaining a comprehensive list of genes, proteins or metabolites that are different between disease and normal is routine today. And yet, the holy grail of high-throughput has not delivered so far. Even though such high-throughput comparisons have become relatively easy to perform, understanding the phenomena that cause the disease is as challenging as ever, if not more so. Signaling and metabolic pathways are complex graphs describing genes signaling and biochemical reactions that take place in various subsystems of the organism. The current methods that aim to help us understand the underlying biological phenomena by using the measured differences to identify significantly impacted pathways are rather unsophisticated. Many if not all such methods of- ten treat the pathways as simple sets of genes, and either ignore or under-utilize the very essence of such pathways: the graphs that describe the complex ways in which genes interact with each other. We are proposing the development of a software product for the analysis of gene signaling and metabolic pathways in the context of high throughput data, such as DNA microarrays. The fundamentals of the approach have been tested through the implementation of tools available for free from the PI's academic web site. These tools have an existing user base of 11,266 registered users who already use and trust our software. This user-base constitutes a unique asset for Advaita. The product we envisage will have a number of unique capabilities including the ability to: i) take into consideration the interactions between specific genes;ii) calculate a unique """"""""impact factor"""""""" that characterizes how impacted a given subsystem of the organism is in the given condition;iii) find the mechanisms of action for diseases and drugs;iv) pinpoint potential points of optimal therapeutic intervention;and v) detect qualitative changes in a living organism by monitoring a large number of parameters (gene expression levels, metabolites, etc.). This product has the potential to: i) shorten the drug development cycle by providing fewer but better drug candidates, ii) help with the understanding of disease and drug mechanisms, iii) detect qualitative changes in biological organisms. The scientific validity of this analysis approach has been verified on real data in a number of applications (several published, others described here as preliminary results). The technical feasibility was demonstrated in over 36,000 benchmark trials. The commercial validity of this product has been verified by implementing a proto- type including the first 2 of the capabilities above. This prototype was already sold to 3 customers in spite of the fact that it only implements a small subset of the final set of capabilities and in spite of the fact that these customers already had access to the software products offered by our competition.
The benefits of the proposed research are expected to impact a number of research areas spanning from cancer, to obesity, to aging as well as any other life science area in which high-throughput methods (e.g. DNA microarrays, protein microarrays, metabolomics, etc.) are used. The biological user community that can benefit from this research includes any life science researcher using such high-throughput methods in any biological domain and any organism, from yeast, to fruit fly, to mouse, to human.
|Talwar, Harvinder; Hanoudi, Samer Najeeb; Geamanu, Andreea et al. (2017) Detection of Cystic Fibrosis Serological Biomarkers Using a T7 Phage Display Library. Sci Rep 7:17745|
|Hanoudi, Samer; Donato, Michele; Draghici, Sorin (2017) Identifying biologically relevant putative mechanisms in a given phenotype comparison. PLoS One 12:e0176950|
|Diaz, Diana; Donato, Michele; Nguyen, Tin et al. (2017) MICRORNA-AUGMENTED PATHWAYS (mirAP) AND THEIR APPLICATIONS TO PATHWAY ANALYSIS AND DISEASE SUBTYPING. Pac Symp Biocomput 22:390-401|
|Bokanizad, Behzad; Tagett, Rebecca; Ansari, Sahar et al. (2016) SPATIAL: A System-level PAThway Impact AnaLysis approach. Nucleic Acids Res 44:5034-44|
|Nguyen, Tin; Tagett, Rebecca; Donato, Michele et al. (2016) A novel bi-level meta-analysis approach: applied to biological pathway analysis. Bioinformatics 32:409-16|
|Tellaroli, Paola; Bazzi, Marco; Donato, Michele et al. (2016) Cross-Clustering: A Partial Clustering Algorithm with Automatic Estimation of the Number of Clusters. PLoS One 11:e0152333|
|Nguyen, Tin; Diaz, Diana; Tagett, Rebecca et al. (2016) Overcoming the matched-sample bottleneck: an orthogonal approach to integrate omic data. Sci Rep 6:29251|
|Bollig-Fischer, Aliccia; Marchetti, Luca; Mitrea, Cristina et al. (2014) Modeling time-dependent transcription effects of HER2 oncogene and discovery of a role for E2F2 in breast cancer cell-matrix adhesion. Bioinformatics 30:3036-43|
|Donato, Michele; Xu, Zhonghui; Tomoiaga, Alin et al. (2013) Analysis and correction of crosstalk effects in pathway analysis. Genome Res 23:1885-93|
|Del Sorbo, Maria Rosaria; Balzano, Walter; Donato, Michele et al. (2013) Assessing co-regulation of directly linked genes in biological networks using microarray time series analysis. Biosystems 114:149-54|
Showing the most recent 10 out of 13 publications